Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    153
    ...
ATC Name B/G Ingredients Dosage Form Price
R06AE09 LEVOTREX G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
C09CA04 ANDARAN G Irbesartan - 300mg 300mg Tablet, film coated 940,435 L.L
G04BE08 CIALIS B Tadalafil - 5mg 5mg Tablet, film coated 6,512,261 L.L
L01EE03 MEKTOVI BioTech Binimetinib - 15mg 15mg Tablet, film coated 257,694,409 L.L
R06AE09 LIVIDA G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
A11AB CYPRO-VITA B Vitamin C - 20mg, Vitamin B3 - 5mg, Vitamin B12 - 2.5mg, Vitamin B6 - 0.6mg, Vitamin B2 - 0.75mg, Vitamin B1 - 0.6mg, Vitamin D3 - 167IU, Vitamin A - 1670IU, Cyproheptadine HCl - 4mg Tablet, film coated 409,552 L.L
C10AA07 CONSIVAS 10 G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 450,187 L.L
N03AX14 KEPPRA B Levetiracetam - 250mg 250mg Tablet, film coated 3,240,855 L.L
R06AE09 ZOLICIN G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 228,453 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 25mg 25mg Tablet, film coated 75,701,015 L.L
C09CA04 GIZLAN G Irbesartan - 300mg 300mg Tablet, film coated 768,678 L.L
C10AA07 CRESOTAB G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 517,379 L.L
G04BE08 DURALIS 5 G Tadalafil - 5mg 5mg Tablet, film coated 1,791,790 L.L
L01EF01 IBRANCE B Palbociclib - 75mg 75mg Tablet, film coated 172,164,216 L.L
L02BX03 ZYTIGA B Abiraterone acetate - 500mg 500mg Tablet, film coated 72,384,396 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated 151,399,262 L.L
C09CA04 IBECARD 300- IPS G Irbesartan - 300mg 300mg Tablet, film coated 564,414 L.L
C10AA07 CRESULIP 10 G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
G04BE08 ENKOR G Tadalafil - 5mg 5mg Tablet, film coated 1,766,193 L.L
C09CA04 IRBAVEL 300 G Irbesartan - 300mg 300mg Tablet, film coated 564,414 L.L
C10AA07 LIPIROSE OBP 10 G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
G04BE08 HEROX G Tadalafil - 5mg 5mg Tablet, film coated 1,416,410 L.L
L02BX03 APO-ABIRATERONE G Abiraterone acetate - 500mg 500mg Tablet, film coated 46,110,590 L.L
G04BE08 LINK G Tadalafil - 5mg 5mg Tablet, film coated 3,926,708 L.L
L02BX03 TEROPROS G Abiraterone acetate - 500mg 500mg Tablet, film coated 47,290,487 L.L
N03AX14 LEVIPRAM 250 G Levetiracetam - 250mg 250mg Tablet, film coated 1,087,873 L.L
C10AA07 PREVAST 10-IPS G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
L01EF01 IBRANCE B Palbociclib - 100mg 100mg Tablet, film coated 172,164,216 L.L
N03AX14 KEPPRA B Levetiracetam - 500mg 500mg Tablet, film coated 6,478,288 L.L
C09CA04 ZIOREL G Irbesartan - 300mg 300mg Tablet, film coated 575,933 L.L
    ...
    153
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025